April 2025 — As precision medicine and advanced drug delivery technologies continue to gain momentum globally, Litchlab proudly announces the expansion of its CDMO platform dedicated to Mesoporous Silica Nanoparticles (MSNs). This platform empowers the development of complex therapies including anti-cancer agents, vaccines, neurotherapeutics, and immunotherapies, helping biopharma companies scale innovation from lab to clinic.
MSNs are emerging as highly versatile nanocarriers due to their large surface area, tunable pore size, high loading capacity, and ability to be engineered for stimuli-responsive behavior. Litchlab is responding to increasing global demand by offering a fully integrated MSN CDMO solution that includes formulation development, surface functionalization, aseptic manufacturing, and regulatory support.
Surface area >1000 m²/g with tunable pore diameters (2–10 nm)
High drug loading capacity; co-loading of small and large molecules
Controlled dual-drug or multi-modal release profiles
PEGylation, ligand-conjugation (TfR, RGD peptides, antibodies)
pH-, enzyme-, or temperature-sensitive coatings
Core-shell hybrid structures (e.g., MSN@LNP, MSN@polymer) to improve systemic stability and tissue penetration
Designed for responsive degradation in tumor or inflammatory microenvironments
Controlled release of degradation products for long-term safety
Custom MSN synthesis from high-purity or pharmaceutical-grade silica
Encapsulation of small molecules, peptides, proteins, siRNA/mRNA, antibodies, and vaccines
Scalable functionalization: electrostatic adsorption, covalent grafting, layer-by-layer assembly
Formulation development: injectable suspensions, lyophilized powders, hydrogels
Aseptic processing and fill-finish for clinical and commercial GMP
Comprehensive analytical support: particle size, zeta potential, drug loading, release kinetics, degradation profiling
IND/IMPD/NDA dossier preparation and regulatory consultation
| Area | Example Projects |
|---|---|
| Oncology | EGFR/PD-L1-targeted MSN immunotherapy systems |
| mRNA Vaccines | MSN@LNP hybrid particles for enhanced mRNA protection and sustained release |
| CNS Diseases | Brain-targeted MSN delivery for siRNA/small molecules in Parkinson's, Alzheimer's |
| Immunotherapy | MSN + TLR agonists for co-delivery of antigen and immune activators |
| Transdermal/Topical | MSN-microneedle composites for wound healing and skin therapy |
MSN-based delivery platforms have doubled in global pipeline projects since 2020
Projected to become a critical carrier for nucleic acid drugs and personalized therapies by 2030
Regulatory bodies like the FDA and EMA are increasingly recognizing inorganic nanocarriers in guidance documents, clearing the way for future approvals
✔️ Industry-leading MSN design, functionalization & process scale-up
✔️ Integrated from formulation to GMP clinical supply
✔️ Seamless compatibility with liposomes, polymers, hydrogels for combination systems
✔️ Global regulatory experience for IND/NDA submissions
✔️ Rapid, customized, and collaborative development approach
📞 Partner with us to co-develop the next generation of smart nanomedicine.
🔗 www.litchlab.com
📧 Sales@litchlab.com
